

comprising SEQ ID NOS: 1-2358.

In accordance with 37 C.F.R. §1.121(b)(3), please amend the Specification by replacing the Specification as filed (pages 1-486) with the enclosed Substitute Specification (pages 1-486). In accordance with 37 C.F.R. §1.121(b)(3)(iii) and 37 C.F.R. §1.125(b)(2), a marked up version of the Substitute Specification showing all the changes relative to the Specification as filed is attached as Exhibit A; deleted matter is indicated with brackets, and added matter is underlined. As required by 37 C.F.R. §1.125(b)(1), Applicants' Attorney states that the Substitute Specification includes no new matter.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

In the Claims

Please cancel Claims 1-6. ✓✓

Please add new Claims 7-12. ✓✓

-
7. (New) A method for predicting the likelihood that an individual will have an inflammatory bowel disease, comprising the steps of:
- a) obtaining a DNA sample from an individual to be assessed; and
 - b) determining the nucleotide present at one or more of nucleotide positions 610, 514, 218, 425, 197, 112, 233, 608, 143, 317, and 316 relative to the 5' most nucleic acid in SEQ ID NO: 1119, SEQ ID NO: 1124, SEQ ID NO: 1127, SEQ ID NO: 1133, SEQ ID NO: 1142, SEQ ID NO: 1160, SEQ ID NO: 1262, SEQ ID NO: 1294, SEQ ID NO: 1341, SEQ ID NO: 1832, and SEQ ID NO: 1847, respectively,
- wherein the presence of one or more of a guanine at nucleotide position 610, a cytosine at nucleotide position 514, a guanine at nucleotide position 218, a thymine at nucleotide position 425, an adenine at nucleotide position 197, an adenine at nucleotide position 112, a guanine at nucleotide position 233, a thymine at nucleotide position 608, a guanine